"As a result, we are expecting a weaker 1Q18 ahead vs 1Q17. Hence, we maintain our "neutral" rating with an unchanged DCF-derived target price of 72 cents," says analyst Jarick Seet in a Wednesday report.
SINGAPORE (Feb 21): RHB is maintaining its "neutral" call on TalkMed as CEO Dr Ang Peng Tiam is still serving his eight-month suspension, which started on Jul 25 2017 and is expected to be back on March 26 or towards the end of 1Q18.
RHB also expects Dr Ang to take some time before ramping up to full utilisation again.
